UCB: 2026Q2 Earnings

Financial Report Summary for the Latest Period (H1 2026)

UCB reported strong financial performance for the first half of 2026 (H1 2026, ending June 30, 2026):

Total Revenue:Reached €4.27 billion, representing a 22% increase year-over-year (+27% at constant exchange rates).
Net Sales:Rose by 23% to €4.09 billion (+28% CER), driven by commercial momentum across its core growth products.
Adjusted EBITDA:Surged 68% year-over-year (+79% CER) to €1.74 billion, expanding the adjusted EBITDA margin by over 1,000 basis points to 40.7% (up from 29.6% in H1 2025).
Core EPS:Increased by 94% to €6.84 (compared to €3.52 in H1 2025).
Gross Margin:Improved to 82% (up from 79% in H1 2025), benefiting from favorable product mix towards higher-margin growth products.

UCB operates as a single biopharmaceutical segment, categorizing its top-line revenue primary through major core products and geographical markets.

Key Product Revenue Share (H1 2026 Net Sales of €4.09 Billion):

BIMZELX® (bimekizumab): ~37% of net sales (€1.5+ billion). A dual IL-17A/F inhibitor used for moderate-to-severe plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa.
CIMZIA® (certolizumab pegol): ~20% of net sales. An anti-TNF agent indicated for rheumatoid arthritis, psoriasis, and Crohn’s disease.
BRIVIACT® (brivaracetam): ~8% of net sales (€327 million). An antiepileptic therapy for partial-onset seizures, experiencing mild decline following US patent expiry.
FINTEPLA® (fenfluramine): ~6% of net sales (€239 million). Approved for Dravet syndrome and Lennox-Gastaut syndrome.
gMG Portfolio (RYSTIGGO® & ZILBRYSQ®): ~8% of net sales (€330+ million combined). Focused on treating generalized myasthenia gravis.
EVENITY® (romosozumab): ~7% of net sales. An bone-forming agent for postmenopausal osteoporosis.
Other / Mature Products: ~14% of net sales. Includes legacy therapies like Keppra® and Neupro®.

Geographic Revenue Share & Regional Developments:

United States: Represents ~55%–60% of total revenue. Performance was driven by rapid adoption and insurance coverage expansion for BIMZELX® across newly launched indications, alongside growth in FINTEPLA®.
Europe: Represents ~25%–30% of revenue. Maintained stable volume expansion across immunology products, with strong contribution from EVENITY® and BIMZELX®.
International / Rest of World: Represents ~10%–15% of revenue. Growth was supported by market entries and expanding patient access in Japan and emerging markets.

Recent Key Changes:

Portfolio Shift:UCB’s five key growth drivers (BIMZELX, FINTEPLA, RYSTIGGO, ZILBRYSQ, and EVENITY) contributed over 50% of total net sales in H1 2026, up from 39% in H1 2025.
Peak Sales Guidance Revision:Upgraded peak sales expectation for BIMZELX® to at least €7.0 billion (previously ~€6.0 billion), following positive clinical head-to-head trials (e.g., BE BOLD study demonstrating superior joint efficacy vs. risankizumab).
Guidance Upgrade:UCB raised its FY2026 financial outlook: revenue growth is now expected at low-teens to mid-teens CER (up from high single-digit/low double-digit), and Adjusted EBITDA growth is projected in the mid-teens to low-twenties CER.

Next-Quarter Observation Points & Future Outlook:

US Market Commercial Penetration: Track month-over-month prescription growth and reimbursement coverage for BIMZELX® across its full range of FDA-approved indications.
Pipeline Progress:Key updates expected for FINTEPLA® regulatory filings in CDKL5 deficiency disorder and Phase 3 trial initiation in Rett syndrome.
Generics Impact Management: Monitoring market share erosion of BRIVIACT® following loss of US exclusivity in early 2026.
Cost Structure:Operating expenses are expected to step up in H2 2026 due to clinical phase advancements and financing costs from strategic acquisitions (e.g., Candid Therapeutics).

UCB SA (EBR: UCB) stock price experienced noticeable volatility over the past three months (late May to late August 2026):

Price Trend:The stock traded in the range of €250–€275 during June and early July 2026. Following the earnings announcement on July 30, 2026, the stock spiked initially before pulling back into the €215–€225 range in late August 2026.
Market Drivers:
- Positive Catalysts (Late July):The stock initially gained following the strong H1 2026 earnings release, upgraded full-year guidance, and the increased peak sales estimate for BIMZELX® to €7+ billion.
- Broader Market Adjustment (August): Subsequent downward pressure across European healthcare equities and sector-wide profit-taking led shares to consolidate near €222.00, despite solid fundamental results. Analyst consensus target prices remain higher near €240.00.

Back to UCB

Tagged ucb